Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    04291105
Previous Study | Return to List | Next Study

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04291105
Recruitment Status : Recruiting
First Posted : March 2, 2020
Last Update Posted : October 12, 2020
Sponsor:
Collaborator:
Regeneron Pharmaceuticals
Information provided by (Responsible Party):
Vyriad, Inc.

Brief Summary:
This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will concurrently enroll patients with four distinct advanced malignancies in 5 separate tumor cohorts. The four cancers type are NSCLC and melanoma that are progressing on CPI treatment, CPI-naïve HCC, and treatment-naïve Endometrial.

Condition or disease Intervention/treatment Phase
Melanoma Hepatocellular Carcinoma Non Small Cell Lung Cancer Endometrial Cancer Biological: VV1 Biological: Cemiplimab Phase 2

Detailed Description:
Patients with melanoma will be enrolled into two parallel cohorts; in one cohort (Intravenous melanoma cohort) patients will receive IV VV1 and patients in the other cohort (Intratumoral melanoma cohort) will receive both IV VV1 and Intratumoral VV1; both cohorts will receive IV cemiplimab in combination therapy with VV1 treatment. Patients with NSCLC, HCC or endometrial cancer will receive IV VV1 and IV cemiplimab combination therapy.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 152 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Patients With Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Melanoma or Endometrial Carcinoma
Actual Study Start Date : April 24, 2020
Estimated Primary Completion Date : March 2022
Estimated Study Completion Date : March 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Melanoma

Arm Intervention/treatment
Experimental: Melanoma intratumoral
Melanoma, IV & IT VV1 + cemiplimab Patients will receive both intravenous (IV) VV1 and intratumoral (IT) VV1 on Day 1. Will also receveive an infusion of cemiplimab on Day 1.
Biological: VV1
VV1 is to be administered on Day 1
Other Name: VSV-IFNβ-NIS, Voyager V1

Biological: Cemiplimab
Cemiplimab should be given on Day 1 of each 21-day cycle for up to 2 years
Other Name: Libtayo

Experimental: Melanoma
Melanoma, IV + cemiplimab Patients will receive both IV VV1 and cemiplimab on Day 1.
Biological: VV1
VV1 is to be administered on Day 1
Other Name: VSV-IFNβ-NIS, Voyager V1

Biological: Cemiplimab
Cemiplimab should be given on Day 1 of each 21-day cycle for up to 2 years
Other Name: Libtayo

Experimental: Hepatocellular carcinoma
Hepatocellular carcinoma Patients will receive both IV VV1 and cemiplimab on Day 1.
Biological: VV1
VV1 is to be administered on Day 1
Other Name: VSV-IFNβ-NIS, Voyager V1

Biological: Cemiplimab
Cemiplimab should be given on Day 1 of each 21-day cycle for up to 2 years
Other Name: Libtayo

Experimental: Non-small cell lung cancer
Non-small cell lung cancer Patients will receive both IV VV1 and cemiplimab on Day 1.
Biological: VV1
VV1 is to be administered on Day 1
Other Name: VSV-IFNβ-NIS, Voyager V1

Biological: Cemiplimab
Cemiplimab should be given on Day 1 of each 21-day cycle for up to 2 years
Other Name: Libtayo

Experimental: Endometrial cancer
Endometrial cancer Patients will receive both IV VV1 and cemiplimab on Day 1.
Biological: VV1
VV1 is to be administered on Day 1
Other Name: VSV-IFNβ-NIS, Voyager V1

Biological: Cemiplimab
Cemiplimab should be given on Day 1 of each 21-day cycle for up to 2 years
Other Name: Libtayo




Primary Outcome Measures :
  1. Objective response rate (ORR) per imaging assessment [ Time Frame: within 24 months ]
    Percentage of participants with objective response is assessed every six weeks from Cycle 1 Day 1 through disease progression, by investigator review based on RECIST version 1.1


Secondary Outcome Measures :
  1. Incidence of Treatment-Emergent Adverse Events assessed by CTCAE v5.0 [ Time Frame: within 24 months ]
    Safety and tolerability

  2. Serum concentration time [ Time Frame: within 24 months ]
    Serum concentration time data using RT-PCR of VSV-IFNβ-NIS and systemic cemiplimab levels

  3. To investigate the pharmacodynamics (PD) of VV1 by measuring serum IFNβ [ Time Frame: within 24 months ]
    To investigate the pharmacodynamics (PD) of VV1 by measuring serum IFNβ expression



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria

  1. Age ≥18 years on day of signing informed consent.
  2. Specific by tumor cohorts:

    • For the HCC cohort, confirmed diagnosis of inoperable HCC by histology or clinical/radiological criteria. i. No prior therapy with a PD-(L)1 immune checkpoint inhibitor (CPI) (prior sorafenib is permitted). ii. No or one prior line of systemic therapy only. iii. Child Pugh Score A or B7.
    • For the NSCLC cohort, histologically confirmed diagnosis of advanced and/or metastatic NSCLC in which radiological progression has been demonstrated during therapy with a PD(L)1 immune CPI and for which no existing options are felt to provide clinical benefit (only one line of PD-(L)1 therapy is permitted).

    Progression during or following 1 or more prior regimen(s) and no more than 3 prior therapeutic regimens for metastatic disease.

    • For the melanoma cohorts, histologically confirmed diagnosis of advanced and/or metastatic melanoma in which radiological progression has been demonstrated during therapy with a PD(L)1 immune CPI and for which no existing options are considered to provide clinical benefit (only one line of PD(L)1 therapy is permitted). Progression on ipilimumab is not required. Note: For IT melanoma cohort:

      • i. At least one tumor lesion amenable to repeated IT injection via palpation or ultrasound. Injection of deep visceral lesions is not permitted.
      • ii. Agrees to provide a newly obtained biopsy of injected and witness lesions prior to start of study treatment, and to repeat biopsies twice during study treatment, and to providing the acquired tissue for biomarker analysis. Tissue obtained for the biopsy must not be previously irradiated, but a new or progressing lesion in the radiation field is acceptable.
    • For the endometrial cancer cohort, histologically confirmed diagnosis of advanced and/or metastatic endometrioid endometrial adenocarcinoma. Eligible patients will not have had any prior systemic therapy in the metastatic setting.
  3. For patients treated with prior anti-PD-(L)1 therapy:

    • Last dose of anti-PD-(L)1 must be within 12 weeks of initiating study treatment.
    • Patient must have received at least 4 doses on q2w, 3 doses on q3w or 2 doses on q4w schedule of the previous anti-PD-(L)1 therapy.
    • Progression on prior anti-PD-(L)1 therapy must be defined by:
    • Documented radiographic progression on a single radiographic scan, if treatment with anti-PD-(L)1 was ≥ 16 weeks.
    • Documented radiographic progression on two consecutive radiographic scans at least 4 weeks apart, if treatment with anti-PD-(L)1 therapy was between 8 - 16 weeks; if radiographic progression is accompanied with clinical progression, then a single scan assessment may be used.
    • If progression was only in lymph nodes, biopsy to provide histological confirmation of progression in the lymph node is required.
  4. Measurable disease based on RECIST 1.1.

Key Exclusion criteria: Patients meeting any of the following exclusion criteria at screening/Day -1 of first dosing will not be enrolled in the study

  1. Availability of and patient acceptance of an alternative curative therapeutic option.
  2. Recent or ongoing serious infection, including any active Grade 3 or higher per the National Institute of Cancer Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE, v5.0) viral, bacterial, or fungal infection within 2 weeks of registration.
  3. Known seropositivity for and with active infection by the human immunodeficiency virus (HIV).

    • Patients who are seropositive for HIV but are receiving antiviral therapy and show non-detectable viral load and a normal CD4 T cell count for at least 6 months are eligible.

  4. Seropositive for and with evidence of active viral infection with hepatitis B virus (HBV). Patients who are hepatitis B surface antigen (HBsAg) negative and HBV viral DNA negative are eligible.

    • Patients who had HBV but have received an antiviral treatment and show non-detectable viral DNA for 6 months are eligible.
    • Patients who are seropositive because of HBV vaccine are eligible.
  5. Seropositive for and with active viral infection with hepatitis C virus (HCV).

    • Patients who had HCV but have received an antiviral treatment and show no detectable HCV viral DNA for 6 months are eligible.

  6. Known history of active or latent TB (bacillus tuberculosis).
  7. Any concomitant serious health condition, which, in the opinion of the investigator, would place the patient at undue risk from the study, including uncontrolled hypertension and/or diabetes, clinically significant pulmonary disease (e.g., chronic obstructive pulmonary disease requiring hospitalization within 3 months) or neurological disorder (e.g., seizure disorder active within 3 months).
  8. Prior therapy within the following timeframe before the planned start of study treatment as follows:

    • Small molecule inhibitors, and/or other investigational agent: ≤ 2 weeks or 5 half-lives, whichever is shorter.
    • Chemotherapy, other monoclonal antibodies, antibody-drug conjugates, or other similar experimental therapies: ≤ 3 weeks or 5 half-lives, whichever is shorter.
    • Antibody drug conjugates and radioimmunoconjugates or other similar experimental therapies ≤ 6 weeks or 5 half-lives, whichever is shorter.
  9. New York Heart Association (NYHA) classification III or IV, known symptomatic coronary artery disease, or symptoms of coronary artery disease on systems review, or known cardiac arrhythmias (atrial fibrillation or supraventricular tachycardia).
  10. Any known or suspected active organ-threatening autoimmune disease, such as inflammatory bowel disease, autoimmune hepatitis, lupus, or pneumonitis, with the exception of hypothyroidism and type 1 diabetes that are controlled with treatment.
  11. Immunodeficiency or immunosuppression
  12. History of Grade 3 or 4 immune-mediated adverse reaction to immune CPIs.
  13. Toxicities from previous therapies that have not resolved to a Grade 1 or less.
  14. History of non-infectious pneumonitis that required steroids, or current pneumonitis.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04291105


Contacts
Layout table for location contacts
Contact: Steve Kaesshaefer +19737152917 steve.kaesshaefer@Bexonclinical.com
Contact: Barbara Duckett 5072890944 bduckett@vyriad.com

Locations
Show Show 21 study locations
Sponsors and Collaborators
Vyriad, Inc.
Regeneron Pharmaceuticals
Investigators
Layout table for investigator information
Study Chair: Alice Bexon, MD CMO
Study Director: Naimish Pandya, MD Clinical Lead
Layout table for additonal information
Responsible Party: Vyriad, Inc.
ClinicalTrials.gov Identifier: NCT04291105    
Other Study ID Numbers: VYR-VSV2-203
First Posted: March 2, 2020    Key Record Dates
Last Update Posted: October 12, 2020
Last Verified: October 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Vyriad, Inc.:
Solid Tumor
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Melanoma
Carcinoma, Hepatocellular
Endometrial Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Nevi and Melanomas
Adenocarcinoma
Liver Neoplasms
Digestive System Neoplasms
Digestive System Diseases
Liver Diseases
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Uterine Diseases